The C6orf89 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population specifically designed for loss-of-function investigations of the C6orf89 gene in a human embryonic kidney epithelial context. This polyclonal pool harbors targeted disruption of the C6orf89 locus, allowing researchers to systematically interrogate the cellular functions and downstream signaling networks dependent on this bombesin receptor-activated protein while minimizing the confounding effects of clonal selection.
The HEK293T host cell line is a well-established clonal derivative of HEK293, constitutively expressing the SV40 large T antigen. This feature facilitates episomal replication of plasmids bearing the SV40 origin of replication, resulting in high-level transient protein expression and efficient production of recombinant proteins and lentiviral vectors. Originating from human embryonic kidney epithelium, HEK293T cells retain key epithelial traits and are universally adopted for transfection-based assays, signaling pathway analysis, and scalable recombinant protein manufacturing.
The C6orf89 gene encodes a bombesin receptor-activated protein that mediates mitogenic signaling downstream of the gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype-3 (BRS3). Upon ligand binding by bombesin, gastrin-releasing peptide (GRP), or neuromedin B, these receptors couple to G??q/11, stimulating phospholipase C ?? (PLC??) and protein kinase C (PKC). C6orf89 is activated in this cascade and propagates signals through RAF?CMEK?CERK, leading to ERK1/2 phosphorylation and upregulation of cyclin D1 and proliferating cell nuclear antigen (PCNA). Thus, C6orf89 integrates bombesin/GRP signaling with cell cycle progression and epithelial proliferation.
In the HEK293T epithelial background, which endogenously expresses growth factor and GPCR signaling components, disruption of C6orf89 yields a relevant model for dissecting bombesin receptor-mediated epithelial proliferation and homeostasis. HEK293T cells support robust MAPK/ERK activation upon stimulation, making them ideal for examining C6orf89’s role in modulating ERK signaling dynamics. The polyclonal knockout population avoids clonal heterogeneity, allowing more generalized conclusions about C6orf89-dependent phenotypes. Additionally, the epithelial origin of HEK293T provides a suitable context for studying C6orf89 in tissue-relevant processes such as wound healing and proliferation.
These knockout cells are ideal for a range of research applications, including detailed mapping of bombesin/GRP signaling, evaluation of C6orf89-dependent cell proliferation and cell cycle regulation, and epithelial homeostasis studies. The polyclonal knockout model is amenable to high-throughput screening for modulators of C6orf89 function. Typical assays compatible with these cells encompass Western blotting for C6orf89, RT-qPCR, MTT or BrdU proliferation assays, phospho-ERK1/2 immunoblotting or flow cytometry, cell cycle flow cytometry, immunofluorescence microscopy, colony formation, and wound healing assays to monitor epithelial migration. For additional technical information, please contact Ascent Research.
